?Effects of herbal product IMPOHelzavid on improving patients COVID-19 symptoms

INTERVENTION: Intervention 1: Intervention group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the herbal compound two times a day. The herbal capsule contains a mixture of medicinal plant extract powder and is manufactured by the ACECR Institute of Medicinal Plants. The herbal capsule is given as a supplement to patients for twelve days along with standard medications. Intervention 2: Control group: patients in this group in addition to receiving standard medications, take two 500 mg capsules of the placebo two times a day. The placebo capsule contains a toasted powder is manufactured by the ACECR Institute of Medicinal Plants. The placebo capsule is given as a supplement to patients for twelve days along with standard medications. CONDITION: U07.1 COVID‐19 pneumonia. ; COVID‐19, virus identified PRIMARY OUTCOME: Blood oxygen saturation. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Pulse Oximeter. Cough. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire. Shortness of breath. Timepoint: At beginning and daily every 12 hours up to end of the study. Method of measurement: Scoring questionnaire. SECONDARY OUTCOME: Alkaline phosphatase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. ALT. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. Aspartate transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. Creatinine. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. Hospitalization. Timepoint: During the study. Method of measurement: Number. Mortality rate. Timepoint: During the study. Method of measurement: Number. BUN. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. C‐reactive protein. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. ESR. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. Fever. Timepoint: At beginning and then every 12 hours up to end of the study. Method of measurement: Termometer. Alanine transaminase. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. CBC. Timepoint: At beginning and end of the study. Method of measurement: Intravenous blood test. INCLUSION CRITERIA: Patients infected with symptomatic COVID‐19 pneumonia virus Confirmation of coronavirus infection with PCR test Age 20 to 70 years old who have the ability to take oral product Personal desire to participate in the project and the signing of a written consent